CD73: A potential biomarker for anti-PD-1 therapy

Paul A Beavis; Clare Y Slaney; Nicole Milenkovski; Melissa A Henderson; Sherene Loi; John Stagg; Michael H Kershaw; Phillip K Darcy

doi:10.1080/2162402X.2015.1046675

CD73: A potential biomarker for anti-PD-1 therapy

Oncoimmunology. 2015 May 5;4(11):e1046675. doi: 10.1080/2162402X.2015.1046675. eCollection 2015 Nov.

Authors

Paul A Beavis¹, Clare Y Slaney¹, Nicole Milenkovski¹, Melissa A Henderson¹, Sherene Loi¹, John Stagg², Michael H Kershaw³, Phillip K Darcy³

Affiliations

¹ Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
² Department of Immunology; Monash University ; Clayton, Australia ; Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie et Institut du Cancer de Montréal ; Montréal, QC Canada.
³ Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia ; Department of Pathology; University of Melbourne ; Parkville, Australia.

Abstract

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A_2A blockade. Since CD73 is known to be overexpressed in several human cancers and A_2A antagonists have undergone clinical trials for Parkinson's Disease, this combination warrants further investigation.

Keywords: CD73; adenosine; anti-PD-1; cancer; immunotherapy.

Publication types

Research Support, Non-U.S. Gov't